SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers

Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) have had an increasing role in the treatment of ovarian and breast cancers. PARP inhibitors are selectively active in cells with homologous recombination DNA repair deficiency caused by mutations in BRCA1/2 and other DNA repair pathway genes....

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Zhen, Mao, Weiqun, Yang, Hailing, Santiago-O’Farrill, Janice M., Rask, Philip J., Mondal, Jayanta, Chen, Hu, Ivan, Cristina, Liu, Xiuping, Liu, Chang-Gong, Xi, Yuanxin, Masuda, Kenta, Carrami, Eli M., Chen, Meng, Tang, Yitao, Pang, Lan, Lakomy, David S., Calin, George A., Liang, Han, Ahmed, Ahmed A., Vankayalapati, Hariprasad, Bast, Robert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151707/
https://www.ncbi.nlm.nih.gov/pubmed/35642638
http://dx.doi.org/10.1172/JCI146471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151707/
https://www.ncbi.nlm.nih.gov/pubmed/35642638
http://dx.doi.org/10.1172/JCI146471

Ejemplares similares